Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
This single-blind, placebo-controlled, crossover study (n=6) assessed the psychological effects and tolerability of ayahuasca (35, 52.5, 75mg DMT/70kg) in healthy male volunteers with prior experience. The study found dose-dependent increases in various psychological effects, with the tea being well-tolerated from a cardiovascular perspective, though modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. Ayahuasca induced changes in perceptual, affective, cognitive, and somatic spheres, with stimulatory and visual psychoactive effects of longer duration and milder intensity than intravenously administered DMT.
Authors
- Jordi Riba
- Maria Barbanoj
Published
Abstract
Rationale
Ayahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This tea has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe.
Objectives
In the present study, the psychological effects and tolerability of ayahuasca were assessed.
Methods
Three increasing doses of encapsulated freeze-dried ayahuasca (0.5, 0.75, and 1.0 mg DMT/kg body weight) were administered to six healthy male volunteers with prior experience in the use of this tea, in a single-blind crossover placebo-controlled clinical trial.
Results
Ayahuasca produced significant dose-dependent increases in five of the six subscales of the Hallucinogen Rating Scale, in the LSD, MBG, and A scales of the Addiction Research Center Inventory, and in the liking, good effects and high visual analogue scales. Psychological effects were first noted after 30-60 min, peaked between 60-120 min, and were resolved by 240 min. The tea was well tolerated from a cardiovascular point of view, with a trend toward increase for systolic blood pressure. Modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. The overall experience was regarded as pleasant and satisfactory by five of the six volunteers, while one volunteer experienced an intensely dysphoric reaction with transient disorientation and anxiety at the medium dose and voluntarily withdrew from the study.
Conclusions
Ayahuasca can be described as inducing changes in the perceptual, affective, cognitive, and somatic spheres, with a combination of stimulatory and visual psychoactive effects of longer duration and milder intensity than those previously reported for intravenously administered DMT.
Research Summary of 'Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers'
Introduction
Ayahuasca is a traditional South American psychoactive brew that contains N,N-dimethyltryptamine (DMT) together with β-carboline alkaloids (harmine, harmaline, tetrahydroharmine) that inhibit monoamine oxidase (MAO), allowing orally ingested DMT to reach the systemic circulation. Use of the tea for magico-religious and therapeutic purposes in the Amazon basin has spread to parts of Europe and North America, raising public health interest in its somatic, psychological, and neurophysiological effects. Previous literature indicates that parenteral DMT produces intense, short-lived psychedelic experiences, but oral DMT is normally inactive unless co-administered with a MAO inhibitor, and systematic clinical data on standardised ayahuasca preparations are limited. Riba and colleagues set out to characterise the subjective effects and tolerability of three increasing oral doses of a freeze-dried ayahuasca preparation in healthy volunteers. The study aimed to document dose-related psychological effects using standardised scales and to monitor cardiovascular, somatic and laboratory measures, as part of a wider programme to clarify the pharmacology of ayahuasca in humans.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001). Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology, 154(1), 85-95. https://doi.org/10.1007/s002130000606
References (3)
Papers cited by this study that are also in Blossom
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
Cited By (97)
Papers in Blossom that reference this study
Bonomo, Y. A., Norman, A. F., Collins, L. et al. · Frontiers in Psychiatry (2025)
Aicher, H. D., Wicki, I. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I. et al. · Neuropsychopharmacology (2025)
Egger, K., Redondo, J. J., Müller, J. et al. · Biomedicine & Pharmacotherapy (2025)
Ables, J. L., Israel, L., Wood, O. et al. · Journal of Psychopharmacology (2024)
Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Psychoactive Drugs (2024)
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · NeuroImage (2024)
Show all 97 papersShow fewer
Apud, I., Scuro, J., Rodríguez, L. et al. · Journal of Psychoactive Drugs (2023)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)
Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)
Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Radakovic, C., Radakovic, R., Peryer, G. et al. · Journal of Psychedelic Studies (2022)
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M. et al. · Frontiers in Psychology (2022)
Ruffell, S. G. D., Gandy, S., Tsang, W. et al. · Psyarxiv (2022)
Jiménez, J. H., Bouso, J. C. · Journal of Psychopharmacology (2022)
Kohek, M., Ona, G., Dos Santos, R. G. et al. · Journal of Psychoactive Drugs (2022)
Madrid-Gambin, F., Gomez-Gomez, A., Busquets-Garcia, A. et al. · Biomedicine & Pharmacotherapy (2022)
Ramaekers, J. G. · Psychopharmacology (2022)
Barker, S. A. · Psychopharmacology (2022)
Schenberg, E. E., Gerber, K. · Transcultural Psychiatry (2022)
Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)
Brabec de Mori, B. · Frontiers in Psychology (2021)
van Oorsouw, K., Uthaug, M. V., Mason, N. L. et al. · Journal of Psychedelic Studies (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Daldegan-Bueno, D., Favaro, V. M., Tófoli, L.F. et al. · Journal of Psychoactive Drugs (2021)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Rush, B., Marcus, O., García, S. et al. · Frontiers in Pharmacology (2021)
Hartogsohn, I. · Frontiers in Pharmacology (2021)
Rocha, J. M., Rossi, G. N., de Lima Osório, F. et al. · Journal of Clinical Psychopharmacology (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Gómez-Sousa, M., Jiménez-Garrido, D. F., Ona, G. et al. · Journal of Clinical Psychopharmacology (2021)
da Silva, M. G., Daros, G. C., de Bitencourt, R. M. · Behavioural Brain Research (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Renelli, M., Fletcher, J., Tupper, K. W. et al. · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity (2018)
Domínguez-Clavé, E., Soler, J., Pascual, J. C. et al. · Psychopharmacology (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Elices, M., Soler, J., Domínguez-Clavé, E. et al. · Frontiers in Pharmacology (2018)
Souza, D. C. D., Pérez, C., Papaseit, E. et al. · Frontiers in Pharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
González, D., Carvalho, M., Aixalá, M. et al. · OMEGA - Journal of Death and Dying (2017)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Journal of Psychedelic Studies (2017)
Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Gallimore, A. R., Strassman, R. J. · Frontiers in Pharmacology (2016)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Maqueda, A. E., Valle, M., Addy, P. H. et al. · International Journal of Neuropsychopharmacology (2015)
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Liester, M. B., Prickett, J. I. · Journal of Psychoactive Drugs (2012)
Riba, J., Mcilhenny, E. H., Valle, M. et al. · Drug Testing and Analysis (2012)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Trichter, S., Klimo, J., Krippner, S. · Journal of Psychoactive Drugs (2009)
Hayashi, T., Vaupel, D. B., Su, T. P. · Science Signaling (2009)
Pires, A. P. S., De Oliveira, C. D. R., Moura, S. et al. · Phytochemical Analysis (2009)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Santos, R. G., Landeira-Fernandez, J., Strassman, R. J. et al. · Journal of Ethnopharmacology (2007)
Gable, R. S. · Addiction (2006)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
McKenna, D. · ACS Chemical Neuroscience (2004)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Riba, J., Rodríguez-Fornells, A., Barbanoj, M. J. · Psychopharmacology (2002)
Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.